Literature DB >> 29520960

Visual complaints of patients with glaucoma and controls under optimal and extreme luminance conditions.

Ronald A J M Bierings1, Frideric L P van Sonderen2, Nomdo M Jansonius1.   

Abstract

PURPOSE: To determine (i) whether, compared to controls, visual complaints of glaucoma patients are more pronounced under extreme luminance conditions than in the optimal luminance condition and (ii) whether complaints belonging to different extreme luminance conditions are associated.
METHODS: We developed a luminance-specific questionnaire and sent it to 221 glaucoma patients (response rate 81%); controls (182) were primarily their spouses. Median (interquartile range) mean deviation of the visual field of the patients' better eye was -4.5 (-10.7 to -1.9) dB. Questions were addressing visual performance under five luminance conditions: presumed optimal (outdoor on a cloudy day), low, high, sudden decrease and sudden increase. We compared percentages of patients and controls who reported visual complaints while performing activities under different luminance conditions.
RESULTS: Percentages of patients and controls with visual complaints were 4 versus 0% (p = 0.02) for optimal luminance and 48 versus 6% (p < 0.001), 22 versus 1% (p < 0.001), 32 versus 1% (p < 0.001) and 25 versus 3% (p < 0.001) for low, high, sudden decrease and sudden increase in luminance. Within the group of glaucoma patients, the frequency of complaints increased significantly with increasing disease severity at a Bonferroni-corrected p value of 0.003 for all but one (p = 0.005) luminance-specific questions that addressed extreme luminance conditions.
CONCLUSION: The concept of (early stage) glaucoma as an asymptomatic disease is only valid with optimal luminance. Differences in visual complaints between glaucoma patients and controls are greater under extreme luminance conditions, especially in the dark. The fact that the cases were aware of their diagnosis could have induced bias.
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adaptation; dark adaptation; glaucoma; luminance; quality of life; screening

Mesh:

Year:  2018        PMID: 29520960     DOI: 10.1111/aos.13695

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  6 in total

1.  Evaluation of the association between macular damage and disability glare in patients with advanced glaucoma.

Authors:  Yun Hsia; Tsing-Hong Wang; Jehn-Yu Huang; Chien-Chia Su
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-22       Impact factor: 3.535

2.  Chronotyping glaucoma patients with the Munich ChronoType Questionnaire: A case-control study.

Authors:  Ronald A J M Bierings; Marijke C M Gordijn; Nomdo M Jansonius
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

3.  Intraocular Pressure Elevation Compromises Retinal Ganglion Cell Light Adaptation.

Authors:  Xiaofeng Tao; Jasdeep Sabharwal; Samuel M Wu; Benjamin J Frankfort
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-10-01       Impact factor: 4.799

4.  Gait in Elderly Glaucoma: Impact of Lighting Conditions, Changes in Lighting, and Fear of Falling.

Authors:  Amanda K Bicket; Aleksandra Mihailovic; Jian-Yu E; Angeline Nguyen; Moneesha Rani Mukherjee; David S Friedman; Pradeep Y Ramulu
Journal:  Transl Vis Sci Technol       Date:  2020-12-16       Impact factor: 3.283

5.  Concept Mapping to Identify Content for a Performance-Based Measure of Low Luminance Vision-Related Activities of Daily Living.

Authors:  Sharon A Bentley; Alex A Black; Gregory P Hindmarsh; Cynthia Owsley; Joanne M Wood
Journal:  Transl Vis Sci Technol       Date:  2022-09-01       Impact factor: 3.048

Review 6.  How do different lighting conditions affect the vision and quality of life of people with glaucoma? A systematic review.

Authors:  Jamie Enoch; Lee Jones; Deanna J Taylor; Carol Bronze; James F Kirwan; Pete R Jones; David P Crabb
Journal:  Eye (Lond)       Date:  2019-12-10       Impact factor: 3.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.